aTyr Pharma, Inc.(US:ATYR) Newsfile·2025-11-11 23:39Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. regarding a federal securities class action lawsuit, with a lead plaintiff deadline set for December 8, 2025 [2][5]. Group 1: Legal Proceedings - The lawsuit alleges that aTyr Pharma and its executives violated federal securities laws by making false and misleading statements about the drug Efzofitimod, particularly regarding its efficacy in allowing patients to taper off steroid usage [5]. - The complaint indicates that the positive statements made by the defendants were misleading, as they concealed material adverse facts about the drug's performance [5]. - Investors who purchased aTyr's securities between January 16, 2025, and September 12, 2025, are encouraged to discuss their legal rights with the firm [2][5]. Group 2: Financial Impact - Following the release of the EFZO-FIT study results, aTyr's stock price plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [6]. - Complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo, indicating limited efficacy [6].